Xtant initiated with bullish view at BTIG, here’s why

BTIG analyst Ryan Zimmerman initiated coverage of Xtant Medical with a Buy rating and $2 price target. Xtant has been an active player in the global spine and orthobiologics markets for 20 years, the analyst tells investors in a research note. The firm says the company’s efforts coupled with the spine market undergoing a period of significant change from consolidation and healthy patient demand “presents investors with an opportunity in small-cap spine that can capitalize on these dynamics at an attractive valuation.”